Table 3.
Association between clinicopathological factors and EC prognosis.
| Variable | Cases (% ) | Median survival (Months) (95% CI) |
Crude HR (95% CI) |
p-value | Adjust HR (95% CI) | p-value |
|---|---|---|---|---|---|---|
| Region of cancer (Typical oesophagostomy) | ||||||
| Upper site | 5 (4.7%) | 12.8 (9.23–16.36) | 1.00 | 1.00 | ||
| Middle site | 73(69.5%) | 8.7 (7.13–10.26) | 0.54 (0.18–1.59) | 0.308 | 0.27 (0.08–1.18) | 0.291 |
| Lower site | 27(25.7%) | 5.4 (0.40–10.39) | 0.58 (0.21–1.62) | 0.271 | 0.31 (0.11–1.78) | 0.286 |
| Histology type | ||||||
| Adenocarcinoma | 28 (26.7%) | 7.3 (3.91–10.69) | 1.00 | 0.785 | 1.00 | 0.696 |
| Squamous cell carcinoma | 77 (73.3%) | 8.8 (5.99–11.61) | 1.06 (0.66–1.71) | 1.10 (0.67–1.81) | ||
| Histology grading (Goseki classification) | ||||||
| Group I,II (well or moderate differentiation) | 33 (31.4%) | 12.8 (5.96–19.63) | 1.00 | 0.637 | 1.00 | 0.048 |
| Group III,IV (poor differentiation) | 72 (68.6%) | 8.7 (6.13–11.26) | 1.15 (0.69–1.92) | 1.22 (1.09–2.82) | ||
| Stage of disease (TNM classification) | ||||||
| Stage I (IA,IB) | 10 (9.5%) | 39.9 (3.32–74.88) | 1.00 | 1.00 | ||
| Stage II | 17 (16.2%) | 20.7 (7.57–33.83) | 1.31 (0.49–3.44) | 0.589 | 0.74 (0.24–3.01) | 0.604 |
| Stage III (IIIA , IIIB) | 21 (22.9%) | 8.6 (7.26–9.93) | 1.48 (1.57–5.43) | 0.038 | 1.25 (1.44–3.42) | 0.046 |
| Stage IV | 57 (51.4%) | 6.1 (4.42–7.78) | 2.71 (1.16–6.36) | 0.022 | 2.68 (1.04–6.93) | 0.041 |
| Metastasis | ||||||
| No | 35 (33.3%) | 12.0 (7.22–16.77) | 1.00 | 0.009 | 1.00 | 0.013 |
| Yes | 70 (66.7%) | 7.1 (3.50–10.69) | 1.81 (1.17–2.88) | 1.52 (1.21–2.48) | ||
| Complication | ||||||
| No | 71 (67.6%) | 8.9 (4.81–12.31) | 1.00 | 0.804 | 1.00 | 0.875 |
| Yes | 34 (32.4%) | 8.1 (7.22–16.77) | 0.94 (0.61–1.47) | 0.96 (0.59–1.56) | ||
Oesophageal cancer (95% CI): 95% confidence interval, HR hazard ratio, adjust for age, gender, BMI and comorbidity by using Cox proportional hazards regression models. p-value from partial likelihood ratio test.